Episodes

  • In the News.. Defining T1D stages, InsuJet approval, T2D dementia risk and more!

    In the News.. Defining T1D stages, InsuJet approval, T2D dementia risk and more!
    Dec 6 2024
    It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A push to change the defined stages of T1D, InsuJet is approved in Canada, new study linked T2D and dementia, new drug looked at to prevent hypoglycemia, big honors for a T1D author and more! Our interview with Clare Edge here. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX The understanding of type 1 has changed a lot in the last 10-15 years, specifically with the definition of stages of the disease. Now some researchers suggest the current 2015 model is ready for another update. University of Florida Health diabetes researchers and collaborators last week issued a call to action in The Lancet Diabetes & Endocrinology, urging the development of a more precise method of calculating type 1 diabetes risk. Under the current staging system, this is Stage 1 of the disease, when a patient does not yet have elevated blood sugar but has two or more of these autoantibodies in the blood. Stage 2 is diagnosed when blood sugar begins to rise, indicating a dysfunctional pancreas in a patient who does not yet have clinical type 1 diabetes. That comes in Stage 3 with high blood sugar and, eventually, the classic symptoms of the disease, including frequent urination, weight loss and fatigue. Jacobsen, however, said the staging system requires more precision. This is especially important as the current staging model determines if a patient is eligible to receive a drug therapy called teplizumab, the only Food and Drug Administration-approved medication that can delay the onset of type 1 diabetes by an average of two years. The staging system, however, does not include a patient’s age and these researchers say additional markers that would be important to consider include a greater array of abnormal metabolic measures beyond blood sugar and the presence of more autoantibodies. https://www.gainesville.com/story/news/healthcare/2024/12/04/uf-health-scientists-propose-update-to-type-1-diabetes-staging-system/76734459007/ XX A product called InsuJet gets approval in Canada. Made by NuGen Medical Devices, InsuJet™ is a needle-free injection system. It’s already approved for sale in 42 countries – not yet the US. Their website says InsuJet’s jet-injected fluid penetrates the skin through a small orifice of a special nozzle, creating a thin, high pressure stream. This way, insulin doesn’t remain around the place of injection, like it does with a needle. Instead, with InsuJet, the insulin is deposited into the subcutaneous tissue where it’s easily absorbed and acts faster– saving you money, time, and discomfort. https://finance.yahoo.com/news/nugen-announces-canada-wide-launch-221500674.html XX Individuals diagnosed with type 2 diabetes before the age of 50 may be at a higher risk of developing dementia later in life. A study led by researchers at NYU Rory Meyers College of Nursing, says the risk is notably greater among adults with obesity. Type 2 diabetes is a known risk factor for dementia. Although the underlying mechanisms are not fully understood, scientists think that some of the hallmarks of diabetes—such as high blood sugar, insulin resistance, and inflammation—may encourage the development of dementia in the brain. The researchers note that this greater understanding of the connection between diabetes onset, obesity, and dementia may help inform targeted interventions to prevent dementia. https://scitechdaily.com/diagnosed-young-with-diabetes-your-dementia-risk-may-be-higher/ XX Embecta is out of the insulin patch pump business – just months after getting the ok from the FDA. Embecta received FDA clearance for its insulin patch pump in September. The device is indicated for people with Type 1 or Type 2 diabetes and includes a 300-unit insulin reservoir to support people with higher daily insulin needs. However, the ...
    Show More Show Less
    7 mins
  • Diabetes Digital: Bridging the gaps in type 2 care

    Diabetes Digital: Bridging the gaps in type 2 care
    Nov 27 2024

    Finding good diabetes info can be tough – there aren’t enough endos and even if you have a great GP, a lot of information can fall through the cracks. More and more digital services and telehealth options are trying to fill the void here – but of course you want to be careful about quality - and cost. I’m talking to two diabetes educators who want to change how we look at diabetes care, while working inside the complicated system of insurance.

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    Learn more about Diabetes Digital

    Please visit our Sponsors & Partners - they help make the show possible!

    Learn about Dexcom

    Check out US MED

    Find out more about CeQur Simplicity

    Check out VIVI Cap to protect your insulin from extreme temperatures

    Learn more about AG1 from Athletic Greens

    --

    We have a monthly newsletter! Sign up today (no spam we promise)

    Here's where to find us:

    YouTube (new!)

    Facebook (Group)

    Facebook (Page)

    Instagram

    Threads

    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Reach out with questions or comments: info@diabetes-connections.com
    Show More Show Less
    28 mins
  • In the News... World Diabetes Day, Free T1D Care(?!), More Mounjaro info, New pump system, and more!

    In the News... World Diabetes Day, Free T1D Care(?!), More Mounjaro info, New pump system, and more!
    Nov 15 2024
    It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: World Diabetes Day roundup, existing drugs examined for T1D prevention, Blue Circle Health expands its novel T1D care model, Mounjaro studied further, Canada approves a new pumps system, and tragedy in the diabetes community. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Of course, World Diabetes Day was yesterday. November 14 marks the birthday of Sir Frederick Banting. who discovered insulin along with Charles Best in 1922. Lots of the tech companies are taking action.. I’m going to link up a great article highlighting what many of them are doing…. from Medtronics Blue Balloon challenge to Dexcom’s Nick Jonas video and a lot more. https://www.drugdeliverybusiness.com/world-diabetes-day-2024/ XX A new triple combo therapy could restore insulin production in people with type 1 using existing medications. Levicure’s triple-combo oral therapy is already considered very safe, because it involves two drugs approved by the U.S. Food and Drug Administration (FDA) and a well-known supplement. The therapy is a combination of: DPP4-inhibitors, a common type 2 diabetes medication Proton pump inhibitors (PPIs), a drug for severe acid reflux A proprietary version of gamma-aminobutyric acid (GABA), a supplement often used to treat anxiety Levicure says the combined effect can block beta cell destruction, suppress autoimmunity, and restore beta cell function. So far, Levicure’s triple therapy has gone through only one retrospective chart review; it has not been put to the test in a randomized controlled trial https://www.diabetesdaily.com/blog/can-this-triple-combo-oral-therapy-restore-insulin-production-733261/ XX Blue Circle Health is expanding it’s unique approach to type 1 care. Already active in Florida, Maine & Vermont, it will now be in Delaware and Ohio. Blue Circle Health is free and develops a personalized care plan for each participant, tailored to their unique needs, and offers comprehensive multidisciplinary support over a six-month period. It’s paid for by the Helmsley Charitable Trust. The program is available to people 18 years of age and older that speak Spanish or English, regardless of insurance coverage or citizen status. We’ve got an upcoming podcast episode all about Blue Circle coming up soon. https://www.prnewswire.com/news-releases/blue-circle-health-expands-to-delaware-and-ohio-to-address-health-system-barriers-to-type-1-diabetes-care-and-education-302304170.html XX An international team of experts has created the world's first evidence-based guide for eating lower and low carb. The group says until now, people with type 1 diabetes and their healthcare providers have lacked comprehensive resources to help implement this approach safely and effectively. The guide provides essential information for dietitians and nutritionists and empowers them to work collaboratively with individuals and families who are interested in reducing carbohydrates. It’s free and we’ve got the download link in the show notes. https://www.newswire.ca/news-releases/international-team-launches-first-guide-for-carbohydrate-reduction-in-type-1-diabetes-883729104.html XX A new pump system is available in Canada. mylife YpsoPump insulin pump and CamAPS FX hybrid closed-loop algorithm by Health Canada. mylife Loop consists of the mylife YpsoPump, a lightweight intuitive insulin pump, integrated with the CamAPS FX hybrid closed-loop, a mobile phone-based algorithm, and the Dexcom G6 Continuous Glucose Monitoring (CGM) System. Working together, these components provide an innovative, automated insulin delivery (AID) system designed to simplify insulin therapy and improve glycemic control for Canadians living with diabetes. "The approval of the mylife YpsoPump and CamAPS FX marks an important milestone as we bring these advanced ...
    Show More Show Less
    7 mins
  • In the News... Omnipod 5 iPhone update, Libre & Dexcom news, overnight insulin pump and more!

    In the News... Omnipod 5 iPhone update, Libre & Dexcom news, overnight insulin pump and more!
    Nov 1 2024
    It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: iPhone control for Omnipod 5 rolls out, Libre is approved for use in CT scans and MRIs, Dexcom files for 15 day wear, Luna nighttime pump goes to trial, iLet cell trials move forward and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Insulet Corporation announces the full market release of the Omnipod 5 App for iPhone® in the U.S. App allows users to fully control their Omnipod 5 Automated Insulin Delivery System (Omnipod 5) from their compatible iPhone1. For example, users can bolus for a meal, change a Pod, and adjust settings. Importantly, this also means that Omnipod 5 users who have a compatible iPhone no longer need to carry a separate Controller to help manage their insulin delivery requirements. Insulet says that the App for iPhone has been the number one feature requested by Omnipod 5 users. The Omnipod 5 App for iPhone is currently compatible with the Dexcom G6 Continuous Glucose Monitoring (CGM) System and is expected to be compatible with the Dexcom G7 CGM in the U.S. in 2025. The Omnipod 5 App for Android phones is also available to U.S. customers. https://www.businesswire.com/news/home/20241029838744/en/Omnipod%C2%AE-5-App-for-iPhone%C2%AE-Now-Fully-Available-in-the-United-States XX Th FDA says it’s okay to keep on your FreeStyle Libre 2 and 3 for procedures like X-rays, CT scans and MRIs. Abbott said it makes its systems the first and only patient-applied CGM sensors approved for these screenings. Imaging procedures often come as part of diabetes care, Abbott said, especially as diabetes can cause a number of medical complications. The company rigorously tested its Libre 2 and 3 sensors to ensure they remain effective after radiologic procedures. This FDA clearance comes with no changes made to the sensor. https://www.drugdeliverybusiness.com/fda-approves-abbott-cgms-medical-imaging/ XX Tidepool announced a new data integration with Abbott for the company’s FreeStyle Libre continuous glucose monitors (CGMs). The companies aim to deliver cloud-to-cloud integration for an automatic stream of data from patients using Abbott’s CGMs in the U.S. Data streams to Tidepool+, a diabetes data visualization and population health platform. Tidepool+ provides intuitive tracking and visualization of diabetes data to make the data informative and actionable for clinicians, people with diabetes and caregivers. https://www.drugdeliverybusiness.com/tidepool-abbott-data-integration-freestyle-libre/ XX Beta Bionics announced today that it launched the integration of the iLet bionic pancreas with the Abbott (NYSE:ABT) FreeStyle Libre 3 Plus. The companies announced their plan to combine the FreeStyle Libre 3 Plus continuous glucose monitor (CGM) with iLet last month. According to Beta Bionics, this makes iLet the first available automated insulin delivery (AID) system to integrate with Libre 3 Plus in the U.S. iLet users can now update their app and software to gain a choice of integrated CGMs. They can choose between Libre 3 Plus and Dexcom CGMs. Abbott, meanwhile, continues to push forward on the automated insulin delivery integration front. The company recently paired its FreeStyle Libre 2 Plus with Insulet’s Omnipod 5 in Europe. It also announced compatibility with the Tandem Diabetes Care t:slim X2 system in January. Notably, the company also struck a deal with Medtronic in August. They aim to develop CGMs specifically for the medtech giant’s own insulin delivery systems. https://www.drugdeliverybusiness.com/beta-bionics-launches-ilet-abbott-libre/ XX Dexcom is asking the FDA to approve the G7 CGM for 15 days. Right now the G7 has a 10 day wear time. Dexcom also launched the G7 CGM in Australia and rolled out Dexcom ONE+ in France. Some front-office news.. EVP and CCO Teri Lawver plans to retire at the end of the ...
    Show More Show Less
    8 mins
  • In the News... Hurricane aid, Medtronic safety warning, Mounjaro supply update, stem cell T1D success... and more!

    In the News... Hurricane aid, Medtronic safety warning, Mounjaro supply update, stem cell T1D success... and more!
    Oct 11 2024
    It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Hurricane aid for people with diabetes, Medtronic safety warning, stem cell updates for type 1, new study about teens and young adults with type 1, and Ryan Reed returns to racing. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Hurricane Insulin efforts XX Medtronic has notified customers that battery issues with its Minimed 600 and 700 series insulin pumps could cause the devices to stop delivering insulin significantly sooner than expected. A “low battery pump” alert, intended to signal up to 10 hours of remaining battery life, may be displayed on the device even if much less time is left. Medtronic told customers they could contact the company to determine the need for a replacement pump. Medtronic said it received 170 reports of hyperglycemia and 11 reports of diabetic ketoacidosis in the U.S., from January 2023 to September 2024, potentially related to the issue. Pump models including the Minimed 630G, 670G, 770G and 780G systems are affected by the notice. https://www.medtechdive.com/news/Medtronic-Minimed-insulin-pumps-recall-battery-life/729019/ XX A woman has undergone a stem-cell therapy made from her own cells, to treat her type 1 diabetes. Researchers in China discovered the woman did not need to use insulin 75 days after the procedure, and that the stem-cell derived islet cells she was injected with had been engrafted inside her abdomen. the case is the first of its kind, and two more people have been enrolled in the clinical trial in China since, researchers involved in the study told Medical News Today. Other stem-cell based therapies for type 1 and type 2 diabetes are also currently in development and in trials. For this case study, researchers based in Tianjin First Central Hospital, Nankai University, Tianjin, China took fat cells from a 25 year-old woman with type 1 diabetes, and chemically induced them to behave as pluripotent stem cells, a type of cell that can develop into other types of cell. They then used these to create islet cells, which typically exist in the pancreas and create insulin, a hormone that regulates levels of glucose (sugar) in the bloodstream. The patient in this case study had previously had two liver transplants and a failed pancreas transplant due to complications that had arisen due to her diabetes. The induced islet cells made from the patient’s own cells were then injected between the skin and abdominal muscles. Researchers discovered that these successfully engrafted in the patient, including growing their own vasculature. Before the procedure she produced enough insulin to reach her target glycemic range 43.18% of the time, and 4 months later this increased to 96.2% of the time. She was also shown to have lower glycated hemoglobin, which indicated long-term systemic glucose levels at a non-diabetic level. https://www.medicalnewstoday.com/articles/stem-cell-therapy-reverses-type-1-diabetes-in-groundbreaking-case-study XX The state of Texas is accusing major pharmacy benefit managers and drug companies of colluding to raise the cost of insulin. Texas alleged drug manufacturers Eli Lilly, Novo Nordisk and Sanofi raise the price of insulin and then pay an undisclosed amount back to PBMs Optum Rx, Express Scripts and CVS Caremark through a quid pro quo agreement. PBMs then give preferred status on its standard formularies to drugs with the highest list prices, the state said. Insulin costs $2 to produce and could be purchased for $20 in the 1990s but now costs up to $700, the Office of the Attorney General of Texas wrote in a news release. The filing goes so far as to describe a LinkedIn group these executives would use to discuss insulin pricing tactics. The Federal Trade Commission (FTC) recently sued Optum Rx, Express Scripts and Caremark for rising insulin prices and anticompetitive ...
    Show More Show Less
    9 mins
  • In the News... Insulin price lawsuit, new CGM approved, diabetes camp scholarships... and more!

    In the News... Insulin price lawsuit, new CGM approved, diabetes camp scholarships... and more!
    Sep 27 2024
    It’s In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: The FTC sues PBMs over insulin pricing, a new CGM is approved in Europe, more news about GLP-1s but some research says it may not work as well for one population, diabetes camps are invited to apply for grants, and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of steering diabetes patients towards higher priced insulin in order to reap millions of dollars in rebates from pharmaceutical companies. The case accuses UnitedHealth Group Inc's (UNH.N), opens new tab Optum unit, CVS Health Corp's (CVS.N), opens new tab CVS Caremark and Cigna Corp's (CI.N), opens new tab Express Scripts of unfairly excluding lower cost insulin products from lists of drugs covered by insurers. The three companies said in statements that the suit was baseless and defended their business practices, saying that they had lowered insulin prices for businesses, unions and patients. https://www.reuters.com/business/healthcare-pharmaceuticals/us-ftc-sues-drug-gatekeepers-over-high-insulin-prices-2024-09-20/ XX A new study finds metformin, may slow aging. Previous studies on "lower order" species have found that it can delay the onset of age-related diseases. Gotta say, this is only in animal studies right now, not people, human trials are next. https://www.cbsnews.com/boston/news/diabetes-drug-metformin-aging/ XX New research from the Case Western Reserve University School of Medicine identifies a potential new approach to address the opioid overdose epidemic—which has devastated families and communities nationally. The study, published in the journal JAMA Network Open, suggests semaglutide is linked to lower opioid overdoses in people with opioid-use disorder (OUD) and type 2 diabetes (T2D). Semaglutide, a glucagon-like peptide receptor (GLP-1R) molecule that decreases hunger and helps regulate blood sugar in T2D, is also the active component in the diabetes and weight-loss drugs Wegovy and Ozempic. The research team—led by biomedical informatics professor Rong Xu—analyzed six years of electronic records of nearly 33,000 patients with OUD who also had T2D. The researchers used a statistical approach that mimics a randomized clinical trial. They found patients prescribed semaglutide had a significantly lower risk for opioid overdose, compared to those who had taken any of eight other anti-diabetic medications, including other types of GLP-1R-targeting medications. About 107,500 people died from drug overdoses nationally in 2023, mostly from opioids, according to the CDC. Despite effective medications to prevent overdoses from OUD, the CDC estimates only a quarter of those with OUD receive them and about half discontinue treatment within six months. https://medicalxpress.com/news/2024-09-popular-diabetes-weight-loss-drug.html XX New research analyzing the effects of two drugs used to treat type 2 diabetes indicates a consistent lack of cardiovascular and renal benefits in Black populations. The drugs, called sodium-glucose co-transporter 2 inhibitors (SGLT2-Is) and glucogen-like peptide 1 receptor agonists (GLP1-RAs), are some of the newer treatments prescribed to lower blood sugar levels in people with type 2 diabetes. The research findings, published in the Journal of the Royal Society of Medicine, show that for White and Asian populations, SGLT2-Is and GLP1-RAs have beneficial effects on blood pressure, weight control and renal function, and significantly reduce the risk of severe heart problems and kidney disease. However, the research shows no evidence of these beneficial effects in Black populations. ""Whether the differences are due to issues with under-representation of Black populations and low statistical power, or to racial/...
    Show More Show Less
    9 mins
  • Omnipod 5 Brings Automated Insulin Delivery to Type 2 Diabetes

    Omnipod 5 Brings Automated Insulin Delivery to Type 2 Diabetes
    Sep 25 2024

    Automated insulin delivery has been an incredible advancement for insulin pumps. Now, for the first time, the FDA has approved a system for people with type 2. It’s called Omnipod 5. We’re going to talk about how it works, who it helps, and what the company found in their studies of people who use it.

    My guest this week is Dr. Trang Ly, truly one of the pioneers of studying and innovating around automated insulin delivery – or AID – systems. She is the Medical Director at Insulet, the company that makes Omnipod. Prior to joining Insulet, Dr. Ly served as Clinical Assistant Professor in the Division of Pediatric Endocrinology, Stanford University School of Medicine. Dr. Ly began her career as a Pediatric Endocrinologist in the Department of Endocrinology and Diabetes at Princess Margaret Hospital for Children in Perth, Australia.

    Learn more about Omnipod 5 for type 2

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    Please visit our Sponsors & Partners - they help make the show possible!

    Learn about Dexcom

    Check out US MED

    Find out more about CeQur Simplicity

    Check out VIVI Cap to protect your insulin from extreme temperatures

    Learn more about AG1 from Athletic Greens

    --

    We have a monthly newsletter! Sign up today (no spam we promise)

    Here's where to find us:

    YouTube (new!)

    Facebook (Group)

    Facebook (Page)

    Instagram

    Threads

    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Reach out with questions or comments: info@diabetes-connections.com
    Show More Show Less
    29 mins
  • CGM Without a Prescription: Stelo & the Future of Diabetes Care with Dexcom's Jake Leach

    CGM Without a Prescription: Stelo & the Future of Diabetes Care with Dexcom's Jake Leach
    Sep 17 2024

    For the first time, you can buy a continuous glucose monitor over the counter, no prescription needed. This summer we went from no CGMs available this way, to now having two. This week we’re talking about the Dexcom Stelo with the company’s COO Jake Leach. We’ll go through the features, the price, how to order and what you should know before you start a CGM.

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    More information about Stelo from Dexcom here

    Our previous episodes on Stelo here

    Please visit our Sponsors & Partners - they help make the show possible!

    Learn about Dexcom

    Check out US MED

    Find out more about CeQur Simplicity

    Check out VIVI Cap to protect your insulin from extreme temperatures

    Learn more about AG1 from Athletic Greens

    --

    We have a monthly newsletter! Sign up today (no spam we promise)

    Here's where to find us:

    YouTube (new!)

    Facebook (Group)

    Facebook (Page)

    Instagram

    Threads

    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Reach out with questions or comments: info@diabetes-connections.com
    Show More Show Less
    31 mins